Vertex lifts annual revenue forecast on strong cystic fibrosis drug sales

• New cystic fibrosis drug Alyftrek generated $573.6 million in Q2 sales, up significantly from $156.8 million a year ago, while older drug Trikafta posted $2.50 billion in sales, missing estimates of $2.65 billion
• Second-quarter total revenue rose 12% year-over-year to $3.33 billion, beating analyst estimates of $3.23 billion, with quarterly profit reaching $4.73 per share
• The $10 billion Crinetics acquisition supports Vertex's diversification strategy, which already includes treatments for kidney disease (povetacicept), sickle cell (Casgevy), and pain (Journavx)

Vertex Pharmaceuticals Raises 2026 Revenue Forecast on Cystic Fibrosis Drug Strength

Vertex Pharmaceuticals increased its annual revenue guidance on Monday, driven by strong demand for its cystic fibrosis treatments. The company now expects 2026 revenue between $13.1 billion and $13.2 billion, up from its previous range of $12.95 billion to $13.1 billion. The revised forecast exceeds the analyst consensus of $13.07 billion.

Key Financial Performance:

• Q2 total revenue rose 12% year-over-year to $3.33 billion, beating analyst estimates of $3.23 billion
• Quarterly earnings per share reached $4.73
• New cystic fibrosis drug Alyftrek generated $573.6 million in Q2 sales, a significant increase from $156.8 million in the prior-year period
• Older CF drug Trikafta posted $2.50 billion in quarterly sales but missed estimates of $2.65 billion

Strategic Developments:

The revenue outlook excludes Vertex's pending $10 billion acquisition of Crinetics, expected to close in Q3 2026. This deal represents a major diversification move, expanding Vertex's portfolio beyond cystic fibrosis into endocrine disorders. The company is already diversifying with povetacicept for kidney disease, Casgevy for sickle cell disease, and Journavx for pain management.

Market Context:

Cystic fibrosis is a rare genetic disorder affecting salt and water transport in cells, causing severe respiratory and digestive complications. Vertex's dominant position in this therapeutic area continues to drive strong revenue growth, with its CF franchise remaining the core revenue generator despite diversification efforts.

The raised guidance signals management confidence in sustained demand for its CF portfolio and successful execution of its growth strategy.